Mapping the antimicrobial resistance (AMR) landscape requires moving beyond the traditional view of drug development as a linear pipeline and instead understanding it as an interconnected, interdependent system. Each stage, from discovery through stewardship, is tightly coupled, with weaknesses in one segment reverberating across the entire ecosystem.
At the front end, discovery is driven by a network of academic institutions, public funders, and early-stage biotech innovators. Universities such as the University of Oxford, Harvard University, and Rockefeller University remain foundational, combining deep expertise in microbiology, infectious disease, and structural biology with access to advanced research infrastructure. Their work, often curiosity-driven, generates the mechanistic insights and early validation that seed therapeutic development.
This activity is sustained by public and philanthropic funding bodies, including the National Institutes of Health, the Wellcome Trust, the Innovative Medicines Initiative, and others, which provide the non-dilutive capital required to advance early-stage research that would otherwise lack commercial backing. Together, these institutions form a discovery engine that is scientifically productive but economically fragile, particularly in areas such as gram-negative pathogens, where technical complexity and low expected returns have driven many large pharmaceutical companies out of the field.¹
Early-stage biotech companies act as the translational bridge between discovery and development. Firms such as VenatoRx Pharmaceuticals, Nosopharm, Locus Biosciences, and Pherecydes Pharma are advancing novel modalities, from next-generation β-lactamase inhibitors to CRISPR-based antimicrobials and bacteriophage therapies. Yet their ability to progress candidates depends heavily on downstream system integrity.
That dependency becomes most apparent in the translational gap, often referred to as the “valley of death.” Here, organizations such as CARB-X, the Global Antibiotic Research and Development Partnership (GARDP), and the Biomedical Advanced Research and Development Authority (BARDA) play a critical role in advancing candidates through preclinical and early clinical development. These entities provide both funding and technical support, helping to bridge the gap between scientific promise and later-phase clinical studies.² Despite these efforts, this stage remains defined by a severe funding cliff. Advancing a candidate through IND-enabling studies requires millions of dollars, yet access to venture capital remains constrained by weak commercial prospects.11 As a result, many promising programs stall before reaching clinical development.
Clinical Development Bottlenecks
Clinical development presents a distinct set of challenges that differ markedly from those in other therapeutic areas. This stage is led by biotech sponsors, including companies such as Entasis Therapeutics, Venatorx Pharmaceuticals, Iterum Therapeutics, Nabriva Therapeutics, Spero Therapeutics, and Forge Therapeutics, often operating with limited capital while navigating complex regulatory and operational demands.
These sponsors rely heavily on contract research organizations (CROs) such as IQVIA, Parexel, PPD, ICON plc, and Medpace, which provide global trial infrastructure, alongside specialized contributors like Certara for pharmacokinetic and pharmacodynamic modeling. Clinical trial execution is further supported by networks such as the Antibacterial Resistance Leadership Group (ARLG), the European Clinical Research Alliance on Infectious Diseases, and the UK’s National Institute for Health and Care Research Clinical Research Network.
Yet even with this infrastructure, AMR trials remain fundamentally misaligned with traditional clinical models. Resistant infections are sporadic and geographically dispersed, making patient recruitment difficult. Trial designs, often centered on non-inferiority frameworks, can be ill-suited to situations in which existing therapies are no longer effective.³
These challenges underscore a broader insight: clinical development paradigms designed for chronic, high-prevalence diseases are often ill-suited to AMR. Emerging approaches, including platform trials, adaptive designs, and globally coordinated trial networks, offer a path forward but remain underutilized.
Manufacturing and Supply Resilience
Once an antimicrobial candidate succeeds clinically, its impact depends on the resilience of a highly distributed manufacturing ecosystem. This network includes CDMOs such as Recipharm, Lonza, Catalent, Almac Group, and Delpharm, alongside manufacturers like Hikma Pharmaceuticals that operate with CDMO-like capabilities in injectables.
Upstream, API production is concentrated among players such as ACS Dobfar, Sandoz, Teva Pharmaceutical Industries, Aurobindo Pharma, Zhejiang Hisun Pharmaceutical, and North China Pharmaceutical Group. These companies form the backbone of global antibiotic supply, yet their geographic concentration introduces systemic risk. A significant proportion of antibiotic APIs are produced in China and India, creating vulnerability to geopolitical disruption, regulatory shifts, and environmental constraints.⁴
Economic realities compound this risk. Antibiotics are typically low-margin, low-volume products, making them less attractive than oncology, rare disease, or biologics programs. As a result, manufacturers must continuously balance capacity allocation, often deprioritizing antimicrobial production.
The COVID-19 pandemic exposed the fragility of this system, with disruptions to raw materials and logistics triggering shortages across multiple drug classes.² These dynamics reinforce a critical point: even clinically successful antibiotics can fail to reach patients if manufacturing systems are not economically sustainable.
Market Failure and Commercial Exit
At commercialization, the AMR ecosystem faces one of its most well-documented failures: a market that fails to reward innovation.
Recent history provides multiple examples. Companies such as Achaogen and Melinta Therapeutics entered bankruptcy shortly after bringing new antibiotics to market, highlighting a structural disconnect between regulatory approval and commercial viability.⁵
This paradox reflects a fundamental misalignment. Antibiotics are designed to be used sparingly to preserve efficacy, yet traditional pharmaceutical business models are volume-based. Emerging policy approaches seek to address this issue. “Delinkage” models propose separating revenue from sales volume, while subscription-based systems, such as those piloted in the United Kingdom and proposed in the United States through the PASTEUR Act, provide fixed payments for access to critical antibiotics.⁶
Without such reforms, the antibiotic pipeline will remain unstable, not due to a lack of innovation, but because the system and revenue models are not structured properly to sustain it.
Stewardship, Access, and Distribution
The final stage of the AMR supply chain determines how antimicrobials are used in practice. Hospitals, governments, NGOs, and global health organizations are responsible for balancing access with appropriate use.
This creates a persistent tension. In some regions, antibiotics are overused due to limited regulation and diagnostic capacity. In others, access remains constrained, with essential medicines unavailable or unaffordable. The World Health Organization has established global stewardship frameworks emphasizing optimized prescribing, surveillance, and education, yet implementation remains uneven.¹
Diagnostics and Surveillance
Diagnostics and surveillance function as the information backbone of the AMR system. Diagnostic companies, clinical laboratories, and public health agencies generate and analyze data that inform treatment decisions and track resistance patterns.
Despite their importance, these systems remain underdeveloped. Many healthcare settings still rely on empirical treatment due to a lack of rapid diagnostics, contributing to inappropriate antibiotic use and accelerating resistance.³
The Missing Link: Financing and Incentive Alignment
Across every node of the AMR supply chain, a common theme emerges: misaligned incentives.
Push funding mechanisms, including grants and early-stage investments from organizations such as CARB-X and BARDA, have revitalized discovery and supported translational progress. However, without complementary pull incentives, products struggle to achieve commercial sustainability.
The result is a fragmented system in which each stakeholder optimizes for its own mandate, whether scientific innovation, financial return, or public health outcomes, but the system as a whole fails to deliver consistent impact.
Integration: From Fragmentation to Function
The AMR supply chain today is defined not by a lack of innovation, but by a lack of coordination.
Public–private partnerships, including CARB-X and GARDP, demonstrate how stakeholders can be aligned across academia, industry, and government. Expanding these models, alongside shared data platforms and end-to-end funding frameworks, will be essential to improving system performance.
The defining insight is clear. A single breakthrough molecule will not solve AMR. It will be solved, or not, by whether we can build a system capable of consistently translating scientific potential into durable clinical impact.
